Ambulatory blood pressure may be designed as the primary efficacy outcome in clinical trials on renal denervation
Comment : Translating guidelines into practice : Interpreting the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL cholesterol lowering in the management of atherosclerotic cardiovascular disease risk
Could pathophysiology failure be ruled out?
Editorial : Function of renal sympathetic nerves
Is isolated systolic hypertension an indication for renal denervation?
It is urgent to investigate predictors of the response of blood pressure to renal denervation
It may be not suitable to perform renal denervation in renal arteries with significant stenosis
Letter by Wang Regarding Article, “Renal Denervation for the Treatment of Cardiovascular High Risk-Hypertension or Beyond?”
Limitations in current clinical trials on renal denervation
Parenteral administration of factor Xa/IIa inhibitors limits experimental aortic aneurysm and atherosclerosis
Renal denervation promotes atherosclerosis in hypertensive apolipoprotein E-Deficient mice infused with angiotensin II
Are you sure you would like to clear your session, including search history and login status?